{"id":8388,"date":"2021-12-16T13:26:58","date_gmt":"2021-12-16T18:26:58","guid":{"rendered":"https:\/\/puyapeptide.net\/product\/lisiraglide-cas-320367-13-3-is-een-glucagon-achtige-peptide-1-glp-1-receptoragonist\/"},"modified":"2021-12-16T13:26:58","modified_gmt":"2021-12-16T18:26:58","slug":"lisiraglide-cas-320367-13-3-is-een-glucagon-achtige-peptide-1-glp-1-receptoragonist","status":"publish","type":"product","link":"https:\/\/puyapeptide.net\/nl\/product\/lisiraglide-cas-320367-13-3-is-een-glucagon-achtige-peptide-1-glp-1-receptoragonist\/","title":{"rendered":"Lisiraglide CAS 320367-13-3 is een glucagon-achtige peptide-1 (GLP-1) receptoragonist"},"content":{"rendered":"<h2><strong>Lisiraglide CAS 320367-13-3 is een glucagon-achtige peptide-1 (GLP-1) receptoragonist<\/strong><\/h2>\n<p>Productnaam: Lixisenatide<br \/>\nSynoniemen: Lixisenatide, &gt;98%;lixisenatide;Lixisenatide|Lixisenatide-acetaat;Lixisenatide-acetaat;Lixisenatide USP\/EP\/BP<br \/>\nCAS: 320367-13-3<br \/>\nN61O215H3<br \/>\nMW: 4858.53<br \/>\nEINECS:<br \/>\nProductcategorie\u00ebn:<br \/>\nMol-bestand: 320367-13-3.mol<\/p>\n<p>Lisiraglide is een glucagon-achtig peptide-1 (GLP-1) receptoragonist, een hormoon dat helpt de bloedsuikerspiegel te normaliseren. De veiligheid en werkzaamheid van het medicijn werden ge\u00ebvalueerd in 10 klinische onderzoeken waarbij in totaal 5.400 pati\u00ebnten met type 2-diabetes werden opgenomen. In deze onderzoeken werd lisiramide ge\u00ebvalueerd als monotherapie en in combinatie met andere door de FDA goedgekeurde diabetesmedicatie, waaronder metformine, sulfonylureumderivaten, pioglitazon en basale insuline. In deze onderzoeken verbeterde het gebruik van lisiramide de geglyceerde hemoglobine (een indicator van de bloedglucosespiegels). Bovendien werden in de Cardiovascular Outcomes Trial meer dan 6.000 pati\u00ebnten met type 2-diabetes met een risico op atherosclerotische cardiovasculaire aandoeningen behandeld met lisiramide of placebo. Het gebruik van lisiramide bij deze pati\u00ebnten verhoogde het risico op cardiovasculaire bijwerkingen niet. Lisiragide mag niet worden gebruikt voor de behandeling van pati\u00ebnten met type 1-diabetes of pati\u00ebnten met verhoogde ketonen of urine in het bloed (diabetische ketoacidose). De meest voorkomende bijwerkingen van lisiramide zijn misselijkheid, braken, hoofdpijn, diarree en duizeligheid. Hypoglykemie is een andere vaak voorkomende bijwerking bij pati\u00ebnten die worden behandeld met lisiramide en andere antidiabetica zoals sulfonylureumderivaten en\/of basale krop. Bovendien zijn ernstige overgevoeligheidsreacties (waaronder overgevoeligheid) gemeld in klinische onderzoeken met Lisiragib.<\/p>\n<p>Lixisenatide is een geneesmiddel dat momenteel wordt gebruikt voor de behandeling van diabetes en is ook een GLP-1-receptoragonist. Lixisenatide (Lyxumia) werd in 2013 goedgekeurd voor marketing in Europa en is een injecteerbare diabetesbehandeling op basis van Lixisenatide, die eenmaal per dag wordt toegediend, samen met andere medicijnen of insuline, voor pati\u00ebnten van wie de bloedglucosespiegels alleen onder controle kunnen worden gehouden met medicijnen.&lt; &amp;&gt;<br \/>\n <strong>Opmerking van Lisiraglide CAS 320367-13-3<\/strong><br \/>\nAlleen voor onderzoeksdoeleinden, niet voor menselijk gebruik<\/p>\n","protected":false},"excerpt":{"rendered":"<p>Productnaam: Lixisenatide<br \/>\nAcetaat;Lixisenatide USP\/EP\/BP<br \/>\nCAS: 320367-13-3<br \/>\nMF: C215H347N61O65S<br \/>\nMW: 4858.53<br \/>\nMol Bestand: 320367-13-3.mol<\/p>\n","protected":false},"featured_media":2099,"comment_status":"open","ping_status":"closed","template":"","meta":{"om_disable_all_campaigns":false,"_monsterinsights_skip_tracking":false,"_monsterinsights_sitenote_active":false,"_monsterinsights_sitenote_note":"","_monsterinsights_sitenote_category":0,"site-sidebar-layout":"default","site-content-layout":"default","ast-site-content-layout":"default","site-content-style":"default","site-sidebar-style":"default","ast-global-header-display":"","ast-banner-title-visibility":"","ast-main-header-display":"","ast-hfb-above-header-display":"","ast-hfb-below-header-display":"","ast-hfb-mobile-header-display":"","site-post-title":"","ast-breadcrumbs-content":"","ast-featured-img":"","footer-sml-layout":"","ast-disable-related-posts":"","theme-transparent-header-meta":"default","adv-header-id-meta":"","stick-header-meta":"","header-above-stick-meta":"","header-main-stick-meta":"","header-below-stick-meta":"","astra-migrate-meta-layouts":"default","ast-page-background-enabled":"default","ast-page-background-meta":{"desktop":{"background-color":"","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""},"tablet":{"background-color":"","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""},"mobile":{"background-color":"","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""}},"ast-content-background-meta":{"desktop":{"background-color":"var(--ast-global-color-5)","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""},"tablet":{"background-color":"var(--ast-global-color-5)","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""},"mobile":{"background-color":"var(--ast-global-color-5)","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""}}},"product_brand":[],"product_cat":[342],"product_tag":[1261],"class_list":{"0":"post-8388","1":"product","2":"type-product","3":"status-publish","4":"has-post-thumbnail","6":"product_cat-diabetes-peptide","7":"product_tag-lisiraglide-cas-320367-13-3-is-a-glucagon-like-peptide-1-glp-1-receptor-agonist-nl","8":"desktop-align-left","9":"tablet-align-left","10":"mobile-align-left","12":"first","13":"instock","14":"shipping-taxable","15":"product-type-simple"},"_links":{"self":[{"href":"https:\/\/puyapeptide.net\/nl\/wp-json\/wp\/v2\/product\/8388","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/puyapeptide.net\/nl\/wp-json\/wp\/v2\/product"}],"about":[{"href":"https:\/\/puyapeptide.net\/nl\/wp-json\/wp\/v2\/types\/product"}],"replies":[{"embeddable":true,"href":"https:\/\/puyapeptide.net\/nl\/wp-json\/wp\/v2\/comments?post=8388"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/puyapeptide.net\/nl\/wp-json\/wp\/v2\/media\/2099"}],"wp:attachment":[{"href":"https:\/\/puyapeptide.net\/nl\/wp-json\/wp\/v2\/media?parent=8388"}],"wp:term":[{"taxonomy":"product_brand","embeddable":true,"href":"https:\/\/puyapeptide.net\/nl\/wp-json\/wp\/v2\/product_brand?post=8388"},{"taxonomy":"product_cat","embeddable":true,"href":"https:\/\/puyapeptide.net\/nl\/wp-json\/wp\/v2\/product_cat?post=8388"},{"taxonomy":"product_tag","embeddable":true,"href":"https:\/\/puyapeptide.net\/nl\/wp-json\/wp\/v2\/product_tag?post=8388"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}